AR094960A1 - PAN-ELR⁺ CXC CHEMIOKIN ANTIBODIES - Google Patents
PAN-ELR⁺ CXC CHEMIOKIN ANTIBODIESInfo
- Publication number
- AR094960A1 AR094960A1 ARP140100675A ARP140100675A AR094960A1 AR 094960 A1 AR094960 A1 AR 094960A1 AR P140100675 A ARP140100675 A AR P140100675A AR P140100675 A ARP140100675 A AR P140100675A AR 094960 A1 AR094960 A1 AR 094960A1
- Authority
- AR
- Argentina
- Prior art keywords
- gro
- seq
- antibodies
- antibody
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Abstract
Se proveen anticuerpos que específicamente unen siete quimiocinas ELR⁺ CXC humanas. Los anticuerpos son útiles para el tratamiento de diversas enfermedades inflamatorias/autoinmunes, tal como enfermedad inflamatoria intestinal (IBD), psoriasis en placas, pustulosis palmoplantar; y cáncer, tal como el cáncer renal o cáncer de ovario. Reivindicación 1: Un anticuerpo que neutraliza Gro-a, Gro-b, Gro-g, ENA-78, GCP-2, NAP-2, e IL-8 humana. Reivindicación 7: Un anticuerpo que une Gro-a, Gro-b, Gro-g, ENA-78, GCP-2, NAP-2, e IL-8 humana, el anticuerpo que comprende una cadena ligera y una cadena pesada, en donde la cadena ligera comprende una región variable de cadena ligera (LCVR) y la cadena pesada comprende una región variable de cadena pesada (HCVR), en donde la LCVR comprende LCDR1, LCDR2, LCDR3 y la HCVR comprende HCDR1, HCDR2, HCDR3, en donde LCDR1 es RASQSISNNLH (SEQ ID Nº 7), LCDR2 es YTSRSVS (SEQ ID Nº 8), LCDR3 es GQNNEWPEV (SEQ ID Nº 9), HCDR1 es GYEFTSYWIH (SEQ ID Nº 10), HCDR2 es NISPNSGSANYNEKFKS (SEQ ID Nº 11), y HCDR3 es EGPYSYYPSRXᵃᵃYYGSDL (SEQ ID Nº 20) en donde Xᵃᵃ es E o Q.Antibodies that specifically bind seven human ELR⁺ CXC chemokines are provided. Antibodies are useful for the treatment of various inflammatory / autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, palmoplantar pustulosis; and cancer, such as kidney cancer or ovarian cancer. Claim 1: An antibody that neutralizes Gro-a, Gro-b, Gro-g, ENA-78, GCP-2, NAP-2, and human IL-8. Claim 7: An antibody that binds Gro-a, Gro-b, Gro-g, ENA-78, GCP-2, NAP-2, and human IL-8, the antibody comprising a light chain and a heavy chain, in where the light chain comprises a variable light chain region (LCVR) and the heavy chain comprises a heavy chain variable region (HCVR), wherein the LCVR comprises LCDR1, LCDR2, LCDR3 and the HCVR comprises HCDR1, HCDR2, HCDR3, in where LCDR1 is RASQSISNNLH (SEQ ID No. 7), LCDR2 is YTSRSVS (SEQ ID No. 8), LCDR3 is GQNNEWPEV (SEQ ID No. 9), HCDR1 is GYEFTSYWIH (SEQ ID No. 10), HCDR2 is NISPNSGQANYNEKFKS (SEQ ID No. 11) , and HCDR3 is EGPYSYYPSRXᵃᵃYYGSDL (SEQ ID No. 20) where Xᵃᵃ is E or Q.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361792800P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR094960A1 true AR094960A1 (en) | 2015-09-09 |
Family
ID=50343858
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140100675A AR094960A1 (en) | 2013-03-15 | 2014-02-28 | PAN-ELR⁺ CXC CHEMIOKIN ANTIBODIES |
| ARP220101240A AR125831A2 (en) | 2013-03-15 | 2022-05-10 | PAN-ELR⁺ CXC CHEMOCINE ANTIBODIES |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101240A AR125831A2 (en) | 2013-03-15 | 2022-05-10 | PAN-ELR⁺ CXC CHEMOCINE ANTIBODIES |
Country Status (36)
| Country | Link |
|---|---|
| EP (4) | EP2970447B1 (en) |
| JP (1) | JP6105146B2 (en) |
| KR (1) | KR101745230B1 (en) |
| CN (2) | CN105143259B (en) |
| AP (1) | AP2015008731A0 (en) |
| AR (2) | AR094960A1 (en) |
| AU (1) | AU2014237898B2 (en) |
| CA (1) | CA2901468C (en) |
| CL (1) | CL2015002531A1 (en) |
| CY (1) | CY1120459T1 (en) |
| DK (1) | DK2970447T3 (en) |
| EA (1) | EA029965B1 (en) |
| ES (3) | ES2769123T3 (en) |
| HK (1) | HK1212714A1 (en) |
| HR (1) | HRP20181047T1 (en) |
| HU (1) | HUE038834T2 (en) |
| IL (2) | IL241167B (en) |
| JO (1) | JO3580B1 (en) |
| LT (1) | LT2970447T (en) |
| MA (1) | MA38413A1 (en) |
| ME (1) | ME03094B (en) |
| MX (1) | MX364831B (en) |
| MY (1) | MY171213A (en) |
| NZ (1) | NZ711704A (en) |
| PE (2) | PE20191480A1 (en) |
| PH (1) | PH12015502090B1 (en) |
| PL (1) | PL2970447T3 (en) |
| PT (1) | PT2970447T (en) |
| RS (1) | RS57291B1 (en) |
| SG (1) | SG11201507686TA (en) |
| SI (1) | SI2970447T1 (en) |
| TN (1) | TN2015000377A1 (en) |
| TR (1) | TR201807613T4 (en) |
| TW (1) | TWI612059B (en) |
| UA (1) | UA116008C2 (en) |
| WO (1) | WO2014149733A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2997042B1 (en) * | 2013-05-17 | 2019-08-07 | Centre National de la Recherche Scientifique (CNRS) | Anti-cxcl1, cxcl7 and cxcl8 antibodies and their applications |
| US11485781B2 (en) | 2017-08-17 | 2022-11-01 | Massachusetts Institute Of Technology | Multiple specificity binders of CXC chemokines |
| SG11202005323SA (en) | 2018-01-12 | 2020-07-29 | Bristol Myers Squibb Co | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
| KR102049180B1 (en) * | 2018-04-02 | 2019-11-26 | 고려대학교 산학협력단 | Composition for inducing de-differentiation from somatic cell into induced pluripotent stem cell and method for inducing de-differentiation using the same |
| TWI737000B (en) * | 2018-10-22 | 2021-08-21 | 美商美國禮來大藥廠 | Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativa |
| MX2022004311A (en) | 2019-10-15 | 2022-05-10 | Lilly Co Eli | MAMMAL CELL STRANCES WITH LIPASE/ESTERASE DEFICIENCY GENETICALLY MODIFIED IN A RECOMBINANT MANNER. |
| CN113087795A (en) * | 2019-12-23 | 2021-07-09 | 上海普铭生物科技有限公司 | Antibody aiming at chemokine CX3CL1 and application thereof |
| JP7399305B2 (en) * | 2020-02-12 | 2023-12-15 | イーライ リリー アンド カンパニー | Crystallization of antibodies or antigen-binding fragments |
| TW202206457A (en) * | 2020-04-24 | 2022-02-16 | 美商美國禮來大藥廠 | Pan-elr+ cxc chemokine antibodies for the treatment of respiratory disease |
| CN112358547A (en) * | 2020-09-30 | 2021-02-12 | 浙江大学 | Anti-human CXCL-2 monoclonal antibody 3-D3 and coding gene and application thereof |
| WO2023192478A1 (en) | 2022-04-01 | 2023-10-05 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040091503A1 (en) * | 2002-08-20 | 2004-05-13 | Genitrix, Llc | Lectin compositions and methods for modulating an immune response to an antigen |
| WO2007107002A1 (en) * | 2006-03-22 | 2007-09-27 | Osteopharm Inc. | Markers for the diagnosis, monitoring and prognosis of osteoporosis and for assessing the risk for osteoporosis and for osteoporotic fractures |
| CL2008001071A1 (en) * | 2007-04-17 | 2009-05-22 | Smithkline Beecham Corp | Method to obtain penta-specific antibody against human il-8 / cxcl8, gro-alpha / cxcl1, gro-beta / cxcl2), gro-gamma / cxcl3 and ena-78 / cxcl5; penta-specific antibody; production process of the same; vector, hybridoma or cella that comprises it; pharmaceutical composition; use to treat copd, other diseases. |
| US8647622B2 (en) * | 2007-08-29 | 2014-02-11 | Sanofi | Humanized anti-CXCR5 antibodies, derivatives thereof and their use |
| GB0806812D0 (en) * | 2008-04-15 | 2008-05-14 | Univ Leuven Kath | Citrullinated cytokines |
| MX2010012435A (en) * | 2008-05-14 | 2011-05-03 | Lilly Co Eli | Anti-cxcr4 antibodies. |
| AU2010286516B2 (en) * | 2009-08-28 | 2016-10-06 | Regeneron Pharmaceuticals, Inc. | Antikine antibodies that bind to multiple CC chemokines |
| JP2011097867A (en) * | 2009-11-05 | 2011-05-19 | Kurume Univ | Marker peptide of osteolysis of spinal ligament |
| WO2011100271A2 (en) * | 2010-02-09 | 2011-08-18 | Glaxosmithkline Llc | Novel uses |
| EP2844290A4 (en) * | 2012-05-01 | 2015-12-16 | Glaxosmithkline Llc | NEW ANTIBODIES |
-
2014
- 2014-02-27 TW TW103106908A patent/TWI612059B/en active
- 2014-02-27 JO JOP/2014/0058A patent/JO3580B1/en active
- 2014-02-28 AR ARP140100675A patent/AR094960A1/en active IP Right Grant
- 2014-03-05 EP EP14711899.6A patent/EP2970447B1/en active Active
- 2014-03-05 PT PT147118996T patent/PT2970447T/en unknown
- 2014-03-05 ME MEP-2018-173A patent/ME03094B/en unknown
- 2014-03-05 CN CN201480013248.XA patent/CN105143259B/en active Active
- 2014-03-05 MY MYPI2015703113A patent/MY171213A/en unknown
- 2014-03-05 ES ES18153438T patent/ES2769123T3/en active Active
- 2014-03-05 AP AP2015008731A patent/AP2015008731A0/en unknown
- 2014-03-05 MA MA38413A patent/MA38413A1/en unknown
- 2014-03-05 KR KR1020157024786A patent/KR101745230B1/en active Active
- 2014-03-05 SI SI201430741T patent/SI2970447T1/en unknown
- 2014-03-05 EP EP19190355.8A patent/EP3608336B1/en active Active
- 2014-03-05 DK DK14711899.6T patent/DK2970447T3/en active
- 2014-03-05 PE PE2019001763A patent/PE20191480A1/en unknown
- 2014-03-05 EP EP24199045.6A patent/EP4467566A2/en active Pending
- 2014-03-05 TR TR2018/07613T patent/TR201807613T4/en unknown
- 2014-03-05 ES ES14711899.6T patent/ES2675404T3/en active Active
- 2014-03-05 EA EA201591514A patent/EA029965B1/en not_active IP Right Cessation
- 2014-03-05 JP JP2016500640A patent/JP6105146B2/en active Active
- 2014-03-05 PE PE2015001961A patent/PE20151531A1/en active IP Right Grant
- 2014-03-05 HU HUE14711899A patent/HUE038834T2/en unknown
- 2014-03-05 WO PCT/US2014/020605 patent/WO2014149733A1/en active Application Filing
- 2014-03-05 RS RS20180675A patent/RS57291B1/en unknown
- 2014-03-05 LT LTEP14711899.6T patent/LT2970447T/en unknown
- 2014-03-05 NZ NZ711704A patent/NZ711704A/en unknown
- 2014-03-05 AU AU2014237898A patent/AU2014237898B2/en active Active
- 2014-03-05 PL PL14711899T patent/PL2970447T3/en unknown
- 2014-03-05 EP EP18153438.9A patent/EP3348569B1/en active Active
- 2014-03-05 ES ES19190355T patent/ES2993153T3/en active Active
- 2014-03-05 MX MX2015013053A patent/MX364831B/en active IP Right Grant
- 2014-03-05 SG SG11201507686TA patent/SG11201507686TA/en unknown
- 2014-03-05 CA CA2901468A patent/CA2901468C/en active Active
- 2014-03-05 CN CN201811074266.5A patent/CN109134652B/en active Active
- 2014-05-03 UA UAA201508673A patent/UA116008C2/en unknown
-
2015
- 2015-08-31 TN TN2015000377A patent/TN2015000377A1/en unknown
- 2015-09-03 IL IL24116715A patent/IL241167B/en active IP Right Grant
- 2015-09-09 CL CL2015002531A patent/CL2015002531A1/en unknown
- 2015-09-14 PH PH12015502090A patent/PH12015502090B1/en unknown
-
2016
- 2016-01-21 HK HK16100635.3A patent/HK1212714A1/en unknown
-
2018
- 2018-07-05 HR HRP20181047TT patent/HRP20181047T1/en unknown
- 2018-07-24 CY CY20181100767T patent/CY1120459T1/en unknown
-
2019
- 2019-09-16 IL IL269387A patent/IL269387B/en active IP Right Grant
-
2022
- 2022-05-10 AR ARP220101240A patent/AR125831A2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR094960A1 (en) | PAN-ELR⁺ CXC CHEMIOKIN ANTIBODIES | |
| PE20181326A1 (en) | ANTIBODIES THAT SPECIFICALLY BIND PD-1 AND ITS USES | |
| CU24597B1 (en) | HETERODIMERIC BIESPECIFIC ANTIBODIES THAT BIND CD3 AND CD20 | |
| PE20181089A1 (en) | HUMAN ANTI-CD19 ANTIBODIES WITH HIGH AFFINITY | |
| PE20140247A1 (en) | ANTI-CD38 ANTIBODIES | |
| PE20141568A1 (en) | HUMANIZED ANTIBODIES THAT RECOGNIZE ALPHA-SINUCLEIN | |
| PE20131403A1 (en) | ANTI-OX40 ANTIBODIES AND METHODS OF USING THEM | |
| ES2670621T3 (en) | Antibodies that bind to OX40 and its uses | |
| PE20190737A1 (en) | ANTI-CD27 ANTIBODIES | |
| ES2687282T3 (en) | ANTI-CD134 (OX40) humanized antibodies and their uses | |
| PE20171103A1 (en) | HETERODIMERIC ANTIBODIES THAT BIND TO CD3 AND CD38 | |
| PE20190630A1 (en) | ANTI-TIM-3 ANTIBODIES | |
| PE20151289A1 (en) | ANTIBODIES THAT JOIN THE TL1A AND ITS USES | |
| PA8849001A1 (en) | C-MET ANTIBODIES | |
| MX2019007848A (en) | Anti-pd-1 antibodies and uses thereof. | |
| PE20150002A1 (en) | ANTI-FCRN ANTIBODIES | |
| AR098465A1 (en) | ANTI-a-SINUCLEINE ANTIBODIES AND METHODS OF USE | |
| PE20181054A1 (en) | HUMANIZED ANTI-CD19 ANTIBODIES AND METHODS OF USE | |
| PE20141147A1 (en) | ANTIBODIES TO PCSK9 AND USES OF THEM | |
| AR103713A1 (en) | ANTIBODIES AGAINST TAU AND ITS USES | |
| CO6430469A2 (en) | HUMANIZED ANTIBODIES THAT JOIN CD19 AND ITS USES | |
| AR084315A1 (en) | ANTI-NOTCH1 ANTIBODIES | |
| PE20190208A1 (en) | ANTIBODIES THAT RECOGNIZE TAU | |
| AR098663A1 (en) | MULTIFUNCTIONAL ANTIBODIES THAT JOIN EGFR AND MET | |
| AR109683A1 (en) | ANTIBODIES AGAINST FACTOR XI AND ITS USES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |